Related Experiment Video
Updated: Jun 11, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
Published on: April 5, 2017
In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part I
Laszlo Revesz1, Achim Schlapbach, Reiner Aichholz
1Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland. laszlo.revesz@pharma.novartis.com
Abstract:
Pyrrolo[2,3-f]isoquinoline based amino acids, tetracyclic lactams and cyclic ketone analogues are described as novel MK2 inhibitors with IC(50) as low as 5nM and good selectivity profiles against a number of related kinases including ERK, p38alpha and JNKs. TNFalpha release was suppressed from human peripheral blood mononuclear cells (hPBMCs), and a representative compound inhibited LPS induced TNFalpha release in mice illustrating the potential of this series to provide orally active MK2 inhibitors.
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity
Inhibitors of Bacterial DNA Synthesis
